ArticleJAMA network open2026
Visual Impairment and Cardiovascular Risk Factors in Hispanic and Latino Adults.
Article in JAMA network open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
Importance: Visual impairment (VI) affects approximately 7 million individuals in the US and is associated with adverse outcomes; cardiovascular disease (CVD) risk factors and nonmedical drivers of health (NMDOH) may contribute. Prior research in Mexican American individuals suggested high VI prevalence, but data across more diverse US Hispanic/Latino populations remain limited. Objective: To estimate VI prevalence and assess its associations with CVD risk factors in Hispanic/Latino adults in the US. Design, Setting, and Participants: This cross-sectional study analyzed data from SOL Ojos, an ancillary study of the Hispanic Community Health Study/Study of Latinos (HCHS/SOL). Participants were Hispanic/Latino adults aged 40 years or older from community-based cohorts in Chicago, Illinois, and Miami, Florida, who completed HCHS/SOL visit 3 (2020-2024) and were recruited into SOL Ojos from July 1, 2021, to July 1, 2023. Exposures: Individual and cumulative major CVD risk factors: diabetes, hypercholesterolemia, hypertension, obesity, and smoking. Main Outcome and Measures: Age-standardized VI (visual acuity less than or equal to 20/40 in the better-seeing eye), assessed by habitual visual acuity, best-corrected visual acuity, and uncorrected refractive error (correctable to more than 20/40). Odds ratios (ORs) for VI by CVD risk factors were estimated using logistic regression, sequentially adjusting for traditional, biologic, and NMDOH-related confounders. Age-standardized weighted estimates reflected the target population. Results: Among 3288 participants (mean age, 58.7 [95% CI, 57.9-59.5] years; 61.9% [95% CI, 60.2%-63.5%] female), VI prevalence by habitual visual acuity was 7.1% (95% CI, 5.3%-8.8%) in men vs 7.0% (95% CI, 5.2%-8.8%) in women and by best-corrected visual acuity was 1.8% (95% CI, 1.0%-2.6%) in men vs 2.6% (95% CI, 1.6%-3.7%) in women; VI by uncorrected refractive error was 5.2% (95% CI, 3.7%-6.8%) in men vs 4.4% (95% CI, 3.0%-5.8%) in women. VI prevalence varied across Hispanic/Latino backgrounds in men (habitual visual acuity VI range, 4.1% [95% CI, 1.8%-6.4%] to 16.9% [95% CI, 11.6%-22.2%]; uncorrected refractive error range, 2.3% [95% CI, 0.6%-4.0%] to 13.5% [95% CI, 8.1%-18.9%]) and was highest among Mexican men. In fully adjusted models, diabetes was associated with VI assessed by best-corrected visual acuity (OR, 4.65; 95% CI, 2.42-8.91), as were cumulative CVD risk factors vs 1 or none (3 factors: OR, 3.47 [95% CI, 1.45-8.33]; ≥4 factors: OR, 9.80 [95% CI, 4.34-22.13]). ORs were smaller when VI was assessed by habitual visual acuity (eg, diabetes OR, 2.03 [95% CI, 1.37-3.01]). Conclusions and Relevance: In this cross-sectional study of US Hispanic/Latino adults, VI and CVD risk factor prevalence varied by ethnic background, and diabetes and cumulative CVD risk factors were associated with VI. The findings provide updated prevalence estimates and support the need for longitudinal studies of causal relationships between VI and CVD risk factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.